Alteogen Overview

  • Founded
  • 2008

Founded
  • Status
  • Public

  • Employees
  • 116

Employees
  • Stock Symbol
  • 196170

Stock Symbol
  • Share Price
  • $27.87

  • (As of Monday Closing)

Alteogen General Information

Description

Alteogen Inc Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops & markets biobetters and biosimilars by partnerships with pharmaceutical companies. It focuses on the areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
KRX
Primary Office
  • 62, Yuseong-daero 1628beon-gil
  • Yuseong-gu
  • Daejeon, 34054
  • South Korea
+82 000-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alteogen Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.87 $27.63 $19.56 - $63.17 $1.44B 51.5M 497K $0.07

Alteogen Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 1,243,634 2,521,596 4,511,691 752,946
Revenue 28,056 35,902 35,933 25,066
EBITDA (1,421) (6,642) (13,490) (1,230)
Net Income 3,305 (3,386) (13,400) (604)
Total Assets 174,589 218,767 145,938 74,226
Total Debt 3,103 3,161 3,602 3,659
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alteogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alteogen‘s full profile, request access.

Request a free trial

Alteogen Patents

Alteogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021320569-A1 Method for producing recombinant hyaluronidase Pending 07-Aug-2020 0000000000
AU-2021211348-A1 Novel hyaluronic acid-hydrolyzing enzyme variant having improved stability and pharmaceutical composition comprising same Pending 23-Jan-2020 0000000000
CA-3137324-A1 Novel hyaluronidase variants with improved stability and pharmaceutical composition containing the same Pending 23-Jan-2020 0000000000
EP-3992285-A1 Novel hyaluronic acid-hydrolyzing enzyme variant having improved stability and pharmaceutical composition comprising same Pending 23-Jan-2020 0000000000
AU-2020248612-A1 Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection Pending 25-Mar-2019 C07K16/32
To view Alteogen’s complete patent history, request access »

Alteogen Executive Team (8)

Name Title Board Seat Contact Info
Soon Jae Park Chief Executive Officer
Sang Woo Kang Chief Financial Officer & Vice President
Seung Joo Lee Chief Technology Officer, Head of R&D center & Vice President
Tae Yon Chun Chief Development Officer
Hye-Shin Chung Ph.D Co-Founder & Chief Scientific Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Alteogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alteogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alteogen‘s full profile, request access.

Request a free trial